Fundraising Fox
Northwest Biotherapeutics
OTC: NWBOBethesda, US · Delaware corporation · 2 known investors
Find your way into Northwest Biotherapeutics
Sign up to see every warm intro you have to Northwest Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Northwest Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.
Founders & leadership
AL
Alton L. BoyntonCo-founder & Chief Scientific Officer
LG
Leslie GoldmanExecutive
Board
NM
Navid MalikBoard director
JJ
Jerry JasinowskiBoard director
JC
J Cofer BlackBoard director
Investors · 2
Vedanta Capitallisted by Vedanta CapitalNew York
How we know: Vedanta Capital's portfolio page · Not right? Tell us
Yorkville AdvisorsreportedMountainside
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$10.9M disclosed across 3 of 5 rounds · 2016–2026
▶$2.6MofferedSep 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$2.6MofferedSep 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jerry J JasinowskiDirector
- Leslie J GoldmanExecutive Officer
- J Cofer BlackDirector
- Navid MalikDirector
- Alton BoyntonExecutive Officer, Director
- Marnix L BoschExecutive Officer
- Linda F PowersExecutive Officer, Director
- Offering amount
- $2.6M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$880KraisedJan 2018 · BiotechnologyRule 506(c)
▶$880KraisedJan 2018 · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Linda F PowersExecutive Officer, Director
- Navid MalikDirector
- Marnix BoschExecutive Officer
- Jerry JasinowskiDirector
- Leslie GoldmanExecutive Officer
- J Cofer BlackDirector
- Alton L BoyntonExecutive Officer, Director
- Amount sold
- $880K
- Minimum investment
- $10K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$52KraisedMay 2017 · 1 investors · BiotechnologyRule 506(b)
▶$52KraisedMay 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- J Cofer BlackDirector
- Robert A FarmerDirector
- Jerry JasinowskiDirector
- Navid MalikDirector
- Leslie GoldmanExecutive Officer
- Alton L BoyntonExecutive Officer, Director
- Linda F PowersExecutive Officer, Director
- Amount sold
- $52K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedMar 2016 · 5 investors · BiotechnologyRule 506(b)
▶$10MraisedMar 2016 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cofer BlackDirector
- Navid MalikDirector
- Alton L. BoyntonExecutive Officer, Director
- Susan BayhDirector
- Linda F. PowersExecutive Officer, Director
- Jerry JasinowskiDirector
- Robert A. FarmerDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Minimum investment
- $595.4K
- Sales commissions
- $700K
- Placement agents
- H.C. Wainwright
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Northwest Biotherapeutics.
Frequently asked questions
- What does Northwest Biotherapeutics do?
- NW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.
- Who founded Northwest Biotherapeutics?
- Northwest Biotherapeutics was founded by Alton L. Boynton.
- Who are Northwest Biotherapeutics's investors?
- Northwest Biotherapeutics's investors include Vedanta Capital, Yorkville Advisors.
- How much funding has Northwest Biotherapeutics raised?
- Northwest Biotherapeutics has disclosed $10.9M raised across 3 of its 5 known rounds.
- Where is Northwest Biotherapeutics headquartered?
- Northwest Biotherapeutics is headquartered in Bethesda, US.